您是第 10662518 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

5637人膀胱癌细胞(STR鉴定)

英文名:5637
货号:ZQ0114
价格:¥1400.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

5637人膀胱癌细胞(STR鉴定)

¥1400.00
+

5637人膀胱癌细胞专用培养基

¥550.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥1950
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

5637人膀胱癌

货号

ZQ0114

产品介绍

5637细胞系是一种人类膀胱癌细胞系,据报道,5637最初是从一位68岁白人男性II级癌患者的膀胱中分离出来的具有上皮形态的细胞系。这种产品在癌症研究中有应用。据报道,该细胞能生成 SCF, IL-1,IL-3,IL-6,G-CSF,GM-CSF等。 

注意事项:
5637细胞较难消化,注意延长消化时间,消化到细胞收缩变圆,轻拍培养瓶侧边,细胞可以滑落方可终止消化。

种属

性别/年龄

/68岁

组织

膀胱

疾病

膀胱癌(NCIt:C4912)

生物安全等级

BSL-1

细胞类型

肿瘤细胞

形态学

上皮细胞 

生长方式

贴壁生长

倍增时间

大约23~36小时

培养基和添加剂

RPMI-1640(中乔新舟 货号:ZQ-200+30%DMEM (中乔新舟  货号:ZQ-100)+10%胎牛血清(中乔新舟  货号:ZQ500-A+1%双抗(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0114

培养条件

空气95% 、二氧化碳5%、37℃。

STR位点信息

Amelogenin: X,Y

CSF1PO: 11
D13S317: 11
D16S539: 9
D5S818: 11,12
D7S820: 10,11
TH01: 7,9
TPOX: 8,9
vWA: 16,18
D3S1358: 15,17
D21S11: 31.2,36
D18S51: 16,18
Penta_D: 11
Penta_E: 10,12
D8S1179: 10,16
FGA: 22
D19S433: 13,15
D2S1338: 25

抗原表达/受体表达

***

基因表达

***

保藏机构

ATCC; DSMZ; 

供应限制

仅供科研使用

货号

ZQ0112

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

保存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、论文标题: Long Noncoding RNA MNX1 antisense RNA 1 Exerts Oncogenic Functions in Bladder Cancer by Regulating miR-218-5p/RAB1A Axis
DOI: 10.1124/jpet.119.262949
发表时间: 2020-03-01
期刊: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
影响因子: 3.561
货号: ZQ0114
产品名称: 5637 cells
原文链接: https://jpet.aspetjournals.org/content/372/3/237.abstract


2、论文标题: MicroRNA‑16‑5p/BIMP1/NF‑κB axis regulates autophagy to exert a tumor‑suppressive effect on bladder cancer
DOI: 10.3892/mmr.2021.12215
发表时间: 2021-06-13
期刊: Molecular Medicine Reports
影响因子: 2.952
货号: ZQ0114
产品名称: 5637 cells

原文链接: https://www.spandidos-publications.com/10.3892/mmr.2021.12215



3、PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)


4、PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)


5、PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)


6、PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


7、PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


8、PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


9、PubMed=23401075; DOI=10.1002/path.4176
Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)


10、PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)


11、PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)


12、PubMed=24459064; DOI=10.1007/s13277-013-1604-3
Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I.P., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Tumor Biol. 35:4599-4617(2014)


13、PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)


14、PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)


15、PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)


16、PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)


17、PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


18、PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K., Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)


19、PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)


20、PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


21、PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


22、PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)



公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqx...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号